Clinical Trial Update: Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC [Phase 3]

View source ↗

Summary

Pfizer is conducting a Phase 3 study of talazoparib in combination with enzalutamide for men with DDR gene-mutated metastatic castration-sensitive prostate canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-sensitive Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)
• Talazoparib (talazoparib)

Snippet

Sponsor: Pfizer | Conditions: Prostate Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING